A recent study conducted by researchers at the University of Oklahoma College of Medicine at OU Health Sciences has shed light on the benefits of precision medicine based on race/ethnicity. Precision medicine is an emerging approach to healthcare that personalizes treatment strategies based on a patient’s genetics, diseased tissue, and other factors. The study highlights the racial disparities in cancer treatment and the importance of considering race/ethnicity when developing personalized treatment plans.
Traditionally, most cancer specimens used for research and treatment development come from individuals who are white. This lack of diversity in research samples has led to a blind spot in treatment development, as genetic predispositions toward cancer in non-white races and ethnicities may have been overlooked. However, advancements in technology have made it possible to analyze cancer disparities at the molecular level, providing evidence for differences between racial/ethnic groups.
The study, led by Hiroshi Yamada, Ph.D., and Chinthalapally V. Rao, Ph.D., from the University of Oklahoma, and Upender Manne, Ph.D., from the University of Alabama, focused on colon cancer specimens from American Indian patients in Oklahoma and African American patients in Alabama. By analyzing gene expression and cytokines, the researchers found significant differences between these non-white populations and white Americans. These differences, which can impact the effectiveness of colon cancer drugs, highlight the need for personalized treatments that consider race/ethnicity.
Yamada emphasizes that studying racial/ethnic groups’ biological patterning is crucial for understanding disparities in cancer outcomes. Biological patterning arises from social constructs, dietary habits, geographic locations, and cultural practices, making race an important trait to consider in research. By identifying specific cancer traits in non-white populations, researchers can develop precision medicine approaches that improve health outcomes for minority groups facing cancer.
The study not only provides valuable insights into colon cancer prevention and treatment in American Indian and African American populations but also highlights the need for more diverse samples in cancer research. Yamada hopes that his study raises awareness about the shortage of cancer specimens from non-white populations and encourages efforts to diversify research samples. Moving forward, he plans to investigate the function of genes influencing colon cancer development and treatment outcomes in American Indian and African American populations.
Colon cancer is one of the most common cancers diagnosed in the United States, affecting both men and women. By incorporating molecular analysis into cancer research, scientists can better understand cancer disparities and identify specific traits that can be targeted with precision medicine. This personalized approach has the potential to significantly improve health outcomes in minority populations facing cancer.
In conclusion, the study highlights the importance of precision medicine based on race/ethnicity in improving cancer treatment outcomes. By considering the molecular differences between racial/ethnic groups, researchers can develop personalized treatments that address the unique needs of non-white populations. This research underscores the need for diverse samples in cancer research and emphasizes the role of molecular analysis in understanding and addressing cancer disparities. With further research and advancements in precision medicine, we can strive towards achieving equitable and effective cancer care for all.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
